Clinical trials
Observational Aortic Dissection trials with unknown status
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
35 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2008 | 1 |
| 2011 | 2 |
| 2013 | 1 |
| 2014 | 1 |
| 2015 | 2 |
| 2016 | 3 |
| 2017 | 1 |
| 2018 | 2 |
| 2019 | 4 |
| 2020 | 5 |
| 2021 | 2 |
| 2022 | 5 |
| 2023 | 5 |
| 2024 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Unknown status | 35 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Qilu Hospital of Shandong University | 4 |
| Central South University | 2 |
| Chinese Medical Association | 2 |
| Hangzhou Endonom Medtech Co., Ltd. | 2 |
| Shanghai Zhongshan Hospital | 2 |
| Xijing Hospital | 2 |
| Associacao para Investigacao e Desenvolvimento da Faculdade de Medicina - CETERA | 1 |
| Beijing Institute of Heart, Lung and Blood Vessel Diseases | 1 |
| Centre Hospitalier Universitaire de Besancon | 1 |
| Chinese Academy of Medical Sciences, Fuwai Hospital | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Aortic Dissection | 35 |
| Aortic Diseases | 5 |
| Aortic Aneurysm | 4 |
| Aortic Aneurysm, Thoracic | 4 |
| Disease | 3 |
| Acute Kidney Injury | 2 |
| Aneurysm, False | 2 |
| Pulmonary Embolism | 2 |
| Vascular Diseases | 2 |
| Aneurysm, Aortic Arch | 1 |
Trials
Showing 1 to 25 of 35. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.